- Generic name
- Ticagrelor
- Strength
- 90 mg
- Dosage form
- Tablet
- Manufactured by
- The ACME Laboratories Ltd.
Ticaflow 90 Tablet
About Ticaflow 90 Tablet
Ticaflow 90 is a tablet from The ACME Laboratories Ltd., with the generic name Ticagrelor. Ticaflow 90 is used in adults to help prevent atherothrombotic events after an acute coronary syndrome.
There are 13 brands of Ticagrelor listed in Bangladesh. The lowest listed price is Belinta 60 mg Tablet at ৳ 35.00 per unit.
What is Ticaflow 90 Tablet?
Ticaflow 90 90 mg is a tablet product of The ACME Laboratories Ltd. that contains Ticagrelor. Its active ingredient is Ticagrelor, which belongs to a group of medicines called anti-platelet drugs. It is prescribed for adults who have had an acute coronary syndrome, such as unstable angina or a heart attack, including those treated with medicines alone or with procedures like angioplasty or bypass surgery. Use it only as your doctor directs.
Uses of Ticaflow 90
Ticaflow 90 is used in adults to help prevent atherothrombotic events after an acute coronary syndrome. It is prescribed whether the patient is managed with medicines alone or with procedures such as percutaneous coronary intervention or coronary artery bypass grafting. It is taken alongside daily aspirin as part of the treatment plan set by the doctor. Your doctor will decide if it is suitable for you.
How to use Ticaflow 90
Swallow the tablet as directed. Swallow the tablet with water. Ticaflow 90 is taken by mouth. Take Ticaflow 90 tablet exactly as your doctor tells you. Do not stop or change the medicine on your own, because stopping can raise the risk of heart attack, stent thrombosis and death. Complete the course exactly as prescribed.
Side effects of Ticaflow 90
Common side effects that have been reported with Ticagrelor include shortness of breath, bleeding, headache, cough, dizziness, nausea, diarrhoea, back pain, fatigue, chest pain, low blood pressure, high blood pressure and atrial fibrillation. The doctor can advise whether you need review or a change in treatment. Because it affects platelets, bleeding is a particular concern. Tell your doctor if any side effect bothers you or does not go away. Contact your doctor if you notice anything unusual after taking it.
Safety and precautions
It is not for people with moderate to severe liver problems or with allergies to the ingredients. Always tell the doctor and pharmacist about all medicines you take, and ask them first before starting or stopping anything. Ticaflow 90 increases the risk of bleeding, so tell the doctor about any bleeding problem, peptic ulcer or past bleeding in the brain.
Frequently asked questions
What is Ticaflow 90 used for?
Ticaflow 90 is used in adults to help prevent atherothrombotic events after an acute coronary syndrome. It is prescribed whether the patient is managed with medicines alone or with procedures such as percutaneous coronary intervention or coronary artery bypass grafting.
How do I use Ticaflow 90 correctly?
Swallow the tablet as directed. Swallow the tablet with water.
What are the side effects of Ticaflow 90?
Common side effects that have been reported with Ticagrelor include shortness of breath, bleeding, headache, cough, dizziness, nausea, diarrhoea, back pain, fatigue, chest pain, low blood pressure, high blood pressure and atrial fibrillation. The doctor can advise whether you need review or a change in treatment.
Can I use Ticaflow 90 in pregnancy or while breastfeeding?
It is not for people with moderate to severe liver problems or with allergies to the ingredients. Always tell the doctor and pharmacist about all medicines you take, and ask them first before starting or stopping anything.
Indications
Pharmacology
Dosage & Administration
A patient who misses a dose of Ticagrelor should take only one 90 mg tablet (the next dose) at its scheduled time. Patients treated with Clopidogrel can be directly switched to Ticagrelor if needed. Switching from prasugrel to ticagrelor has not been investigated.
Treatment is recommended for up to 12 months unless discontinuation of Ticagrelor is clinically indicated. Ticagrelor can be administered with or without food.
Interaction
CYP3A inducers: Avoid use with potent inducers of CYP3A (e.g., rifampin, dexamethasone, phenytoin,carbamazepine and phenobarbital).
Aspirin: Use of Ticagrelor with aspirin maintenance doses above 100 mg reduced the effectiveness ofTicagrelor.
Simvastatin, Lovastatin: Ticagrelor will result in higher serum concentrations of simvastatin and lovastatin because these drugs are metabolized by CYP3A4. Avoid simvastatin and lovastatin doses greater than 40 mg.
Digoxin: Because of inhibition of the P-glycoprotein transporter, monitor digoxin levels with initiation of or any change in ticagrelor therapy.
Other Concomitant Therapy: Ticagrelor can be administered with unfractionated or low-molecular-weight heparin, GPIIb/llla inhibitors, proton pump inhibitors, beta-blockers, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers.
Contraindications
- Hypersensitivity to Ticagrelor or to any of the excipients
- Active pathological bleeding (peptic ulcer)
- History of intracranial haemorrhage
- Moderate to severe hepatic impairment
- Co-administration of Ticagrelor with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, nefazodone, ritonavir, and atazanavir)
Side Effects
Pregnancy & Lactation
Nursing mothers: Available pharmacodynamic/toxicological data in animals have shown excretion of Ticagrelor and its active metabolites in milk. A risk to newborns/infants cannot be excluded. A decision must be made whether to discontinue breastfeeding or to discontinue/abstain from ticagrelor therapy taking into account the benefit of breastfeeding for the child and the benefit of therapy for the women.
Precautions & Warnings
Concomitant Aspirin Maintenance Dose: Use of Ticagrelor with maintenance doses of aspirin above 100 mg decreased the effectiveness of Ticagrelor. Therefore, after the initial loading dose of aspirin (usually 325 mg), use Ticagrelor with a maintenance dose of aspirin of 75-100 mg.
Moderate Hepatic Impairment: Ticagrelor has not been studied in patients with moderate hepatic impairment.
Discontinuation of Ticagrelor: Discontinuation of Ticagrelor will increase the risk of myocardial infarction, stent thrombosis, and death.
Overdose Effects
Storage Conditions
Alternative brands of Ticagrelor
Other brands with the same generic name, cheapest first.
Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.